Breaking News

Scorpion Biological Services Unveils New Biomanufacturing Facility

The $650mn commercial-scale facility will service approximately 144,000 liters of biomfg. capacity across 48 bioreactors.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biopharmaceutical contract development and manufacturing organization (CDMO) Scorpion Biological Services has announced a development partnership with a private developer, the State of Kansas, and local and university affiliates, which will support the construction of a new biodefense-focused large molecule and biologics biomanufacturing facility in Manhattan, KS. The $650 million commercial-scale facility, which will service approximately 144,000 liters of biomanufacturing capacity across 48...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters